Lunai Bioworks Inc. (LNAI) — SEC Filings
Lunai Bioworks Inc. (LNAI) — 50 SEC filings. Latest: 8-K (Apr 28, 2026). Includes 35 8-K, 4 10-Q, 4 SC 13D/A.
View Lunai Bioworks Inc. on SEC EDGAR
Overview
Lunai Bioworks Inc. (LNAI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: Lunai Bioworks, Inc. (formerly RenovaRo Inc.) entered into a material definitive agreement on December 2, 2025. The company, incorporated in Delaware, is in the Pharmaceutical Preparations industry and has its principal executive offices in Los Angeles, CA.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 11 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Lunai Bioworks Inc. is neutral.
Filing Type Overview
Lunai Bioworks Inc. (LNAI) has filed 35 8-K, 4 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13D/A, 1 8-K/A, 1 10-K/A, 1 10-Q/A with the SEC between Apr 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of LNAI's 47 recent filings, 12 were flagged as high-risk, 29 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | $2,819,021 |
| EPS | $0.13 |
| Cash Position | $624,808 |
| Total Assets | $6,960,663 |
Key Executives
- David Weinstein
- James A. McNulty
- Douglas W. Calder
- Board of Directors
- Dr. Steven A. N. De Jong
- Dr. Renova
- Dr. Jonathan Roth
- Dr. Marc Feldmann
- Dr. Kuldip Dave
- William Anderson Wittekind
- Dr. Jonathan L. Cohen
- Patrick T. McCloskey
Industry Context
Lunai Bioworks operates in the AI-driven precision medicine, diagnostics, and biodefense sector. This industry is characterized by rapid technological advancements, significant R&D investment, and a complex regulatory landscape. Companies in this space leverage data analytics and AI to accelerate drug discovery, improve diagnostic accuracy, and develop novel biodefense solutions, often forming strategic partnerships with life sciences firms and government entities.
Top Tags
delisting (8) · company-name-change (7) · corporate-actions (7) · management-change (7) · listing-standards (6) · financials (5) · amendment (5) · Biotechnology (4) · equity-sale (4) · material-definitive-agreement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $2,819,021 | for the three months ended September 30, 2025, compared to a $44,212,036 net loss in 2024 |
| Gain on bankruptcy of subsidiary | $12,019,227 | from Gedi Cube B.V. bankruptcy, a primary driver of net income |
| Accumulated Deficit | $507,643,549 | as of September 30, 2025, indicating significant historical losses |
| Working Capital Deficit | $18,922,114 | as of September 30, 2025, highlighting liquidity challenges |
| Cash | $624,808 | as of September 30, 2025, up from $92,700 at June 30, 2025 |
| Total Operating Expenses | $3,308,360 | for the three months ended September 30, 2025, down from $53,338,554 in 2024 |
| Goodwill Impairment | $47,614,729 | recorded in Q3 2024, absent in Q3 2025, contributing to reduced operating expenses |
| Common Stock Outstanding | 23,432,391 | as of November 10, 2025 |
| Annual Meeting Date | 2025-10-31 | Date of Lunai Bioworks Inc.'s 2025 Annual Meeting of Stockholders |
| Record Date | 2025-10-03 | Date for determining stockholders entitled to vote at the Annual Meeting |
| Shares Outstanding | 23,178,153 | Number of Common Stock shares issued and outstanding and entitled to vote on the Record Date |
| Director Nominees | 4 | Number of directors to be elected at the 2025 Annual Meeting |
| Annual Meeting Time | 10:00 a.m. | Eastern Time for the virtual Annual Meeting |
| Fiscal Year End | 2026-06-30 | Fiscal year for which Sadler, Gibb & Associates LLC is proposed as auditor |
| Aggregate market value of common equity held by non-affiliates | $111,903,627 | as of December 31, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Lunai Bioworks Inc. (LNAI)?
Lunai Bioworks Inc. has 50 recent SEC filings from Apr 2024 to Apr 2026, including 35 8-K, 4 10-Q, 4 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LNAI filings?
Across 50 filings, the sentiment breakdown is: 11 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Lunai Bioworks Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lunai Bioworks Inc. (LNAI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lunai Bioworks Inc.?
Key financial highlights from Lunai Bioworks Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LNAI?
The investment thesis for LNAI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lunai Bioworks Inc.?
Key executives identified across Lunai Bioworks Inc.'s filings include David Weinstein, James A. McNulty, Douglas W. Calder, Board of Directors, Dr. Steven A. N. De Jong and 7 others.
What are the main risk factors for Lunai Bioworks Inc. stock?
Of LNAI's 47 assessed filings, 12 were flagged high-risk, 29 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Lunai Bioworks Inc.?
Forward guidance and predictions for Lunai Bioworks Inc. are extracted from SEC filings as they are enriched.